Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05742607
Title IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Innate Pharma
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | FRA

Additional content available in CKB BOOST